Previous 10 | Next 10 |
LA JOLLA, Calif. , Aug. 3, 2020 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Denis ...
Are These On Your List Of Penny Stocks To Watch Right Now? No matter your stance on penny stocks , having a good list is never a bad idea. It helps you cut through the noise of the rest of the market because you’ve done your research. Well, I should say, I assume that you’ve don...
Regulus Therapeutics (NASDAQ: RGLS ) jumps ~17% PM, on the heels of U.S. Orphan Drug tag for RGLS4326 for Autosomal Dominant Polycystic Kidney Disease (ADPKD). More news on: Regulus Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more ...
LA JOLLA, Calif. , July 29, 2020 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the U.S. Food and Dr...
Regulus Therapeutics ( RGLS -7.8% ) has completed dosing for the Phase 1 multiple ascending dose study for RGLS4326. Top-line results demonstrated that RGLS4326 was well-tolerated with no serious adverse events reported. More news on: Regulus Therapeutics Inc., Healthc...
LA JOLLA, Calif. , July 22, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the completion of dosing fo...
Regulus Therapeutics (NASDAQ: RGLS ): Q1 GAAP EPS of -$0.25 misses by $0.13 . More news on: Regulus Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
LA JOLLA, Calif. , May 14, 2020 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the f...
Regulus Therapeutics (NASDAQ: RGLS ): Q4 GAAP EPS of -$0.23 beats by $0.01 . Revenue of $0.02M (flat Y/Y) beats by $0.01M . Press Release More news on: Regulus Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, ,
LA JOLLA, Calif. , March 12, 2020 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the...
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Continued mechanistic dose resp...
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...